Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model.

Meyer KA, Deraedt MF, Harrington AT, Danziger LH, Wenzler E.

Int J Antimicrob Agents. 2019 Apr 26. pii: S0924-8579(19)30104-9. doi: 10.1016/j.ijantimicag.2019.04.010. [Epub ahead of print]

PMID:
31034937
2.

In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.

Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E.

J Antimicrob Chemother. 2019 Feb 8. doi: 10.1093/jac/dkz010. [Epub ahead of print]

PMID:
30753495
3.

Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection.

Burgos RM, Biagi MJ, Rodvold KA, Danziger LH.

Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1007-1021. doi: 10.1080/17425255.2018.1511702. Epub 2018 Sep 19. Review.

PMID:
30106599
4.

Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants.

Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA; Antibacterial Resistance Leadership Group.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00464-18. doi: 10.1128/AAC.00464-18. Print 2018 Aug.

5.

Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae.

Bunnell KL, Wenzler E, Harrington AT, Danziger LH.

Diagn Microbiol Infect Dis. 2018 Apr;90(4):335-336. doi: 10.1016/j.diagmicrobio.2017.12.007. Epub 2017 Dec 16.

PMID:
29395714
6.

Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.

Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02475-17. doi: 10.1128/AAC.02475-17. Print 2018 Apr.

7.

Clinical use of the polymyxins: the tale of the fox and the cat.

Wenzler E, Bunnell KL, Danziger LH.

Int J Antimicrob Agents. 2018 May;51(5):700-706. doi: 10.1016/j.ijantimicag.2017.12.023. Epub 2018 Jan 3.

PMID:
29305954
8.

Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin.

Bunnell KL, Danziger LH, Johnson S.

Open Forum Infect Dis. 2017 Apr 22;4(2):ofx078. doi: 10.1093/ofid/ofx078. eCollection 2017 Spring.

9.

Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.

Meyer K, Santarossa M, Danziger LH, Wenzler E.

Hosp Pharm. 2017 Mar;52(3):221-228. doi: 10.1310/hpj5203-221.

10.

Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.

Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00464-17. doi: 10.1128/AAC.00464-17. Print 2017 Jul.

11.

Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.

Horn KS, Danziger LH, Rodvold KA, Glowacki RC.

Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):463-472. doi: 10.1080/17425255.2017.1303481. Epub 2017 Mar 17. Review.

PMID:
28264613
12.

A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile.

McConeghy KW, Soriano MM, Danziger LH.

Pharmacotherapy. 2016 Oct;36(10):1095-1101. doi: 10.1002/phar.1832. Epub 2016 Sep 25.

PMID:
27582058
13.

Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Wenzler E, Fraidenburg DR, Scardina T, Danziger LH.

Clin Microbiol Rev. 2016 Jul;29(3):581-632. doi: 10.1128/CMR.00101-15. Review.

14.

Urinary Tract Infections: Resistance Is Futile.

Wenzler E, Danziger LH.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2596-7. doi: 10.1128/AAC.00006-16. Print 2016 Apr. No abstract available.

15.

I.V. minocycline revisited for infections caused by multidrug-resistant organisms.

Colton B, McConeghy KW, Schreckenberger PC, Danziger LH.

Am J Health Syst Pharm. 2016 Mar 1;73(5):279-85. doi: 10.2146/ajhp150290. Review.

PMID:
26896499
16.

Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination.

Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR, Jones RN.

Antimicrob Agents Chemother. 2015 Dec;59(12):7823-5. doi: 10.1128/AAC.01021-15. Epub 2015 Sep 21.

17.

Hepatitis C Management and the Infectious Diseases Pharmacist.

Wenzler E, Dickson W, Vibhakar S, Adeyemi OM, Danziger LH.

Clin Infect Dis. 2015 Oct 1;61(7):1201-2. doi: 10.1093/cid/civ545. Epub 2015 Jul 1. No abstract available.

PMID:
26136390
18.

Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjects.

Justo JA, Mayer SM, Pai MP, Soriano MM, Danziger LH, Novak RM, Rodvold KA.

Antimicrob Agents Chemother. 2015 Jul;59(7):3956-65. doi: 10.1128/AAC.00498-15. Epub 2015 Apr 20.

19.

Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies.

Soriano MM, Danziger LH, Gerding DN, Johnson S.

Open Forum Infect Dis. 2014 Aug 25;1(2):ofu069. doi: 10.1093/ofid/ofu069. eCollection 2014 Sep.

20.

Editorial commentary: improving prescribers to advance antimicrobial stewardship.

Wenzler E, Rodvold KA, Danziger LH.

Clin Infect Dis. 2015 Apr 15;60(8):1259-61. doi: 10.1093/cid/civ021. Epub 2015 Jan 16. No abstract available.

PMID:
25595751
21.

The Antimicrobial Stewardship Approach to Combating Clostridium Difficile.

Wenzler E, Mulugeta SG, Danziger LH.

Antibiotics (Basel). 2015 Jun 17;4(2):198-215. doi: 10.3390/antibiotics4020198. Review.

22.

An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.

Kassamali Z, Jain R, Danziger LH.

Int J Infect Dis. 2015 Jan;30:125-32. doi: 10.1016/j.ijid.2014.10.014. Epub 2014 Nov 5. Review.

23.

Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.

Merker A, Danziger LH, Rodvold KA, Glowacki RC.

Expert Opin Drug Metab Toxicol. 2014 Dec;10(12):1741-50. doi: 10.1517/17425255.2014.972932. Epub 2014 Oct 27. Review.

PMID:
25347329
24.

Outpatient influenza antiviral prescription trends with influenza-like illness in the USA, 2008-2010.

Suda KJ, Regen SM, Lee TA, Easterling JL, Hunkler RJ, Danziger LH.

Int J Antimicrob Agents. 2014 Mar;43(3):279-83. doi: 10.1016/j.ijantimicag.2013.10.025. Epub 2013 Dec 1.

PMID:
24373618
25.

Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections.

Soriano MM, Liao S, Danziger LH.

Expert Rev Anti Infect Ther. 2013 Aug;11(8):767-76. doi: 10.1586/14787210.2013.814767.

PMID:
23977933
26.

Reply to Nation et al.

Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH.

Clin Infect Dis. 2013 Dec;57(11):1657-8. doi: 10.1093/cid/cit525. Epub 2013 Aug 9. No abstract available.

PMID:
23934308
27.

Polymyxins: wisdom does not always come with age.

Kassamali Z, Rotschafer JC, Jones RN, Prince RA, Danziger LH.

Clin Infect Dis. 2013 Sep;57(6):877-83. doi: 10.1093/cid/cit367. Epub 2013 Jul 11. Review.

PMID:
23728146
28.

Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis.

Justo JA, Danziger LH, Gotfried MH.

Ther Adv Respir Dis. 2013 Oct;7(5):272-87. doi: 10.1177/1753465813487412. Epub 2013 May 20. Review.

PMID:
23690368
29.

Behind closed doors: medication storage and disposal in the home.

Wieczorkiewicz SM, Kassamali Z, Danziger LH.

Ann Pharmacother. 2013 Apr;47(4):482-9. doi: 10.1345/aph.1R706. Epub 2013 Mar 27.

PMID:
23535813
30.

How low can you go? Use of low- and standard-dose liposomal amphotericin B for treatment of invasive fungal infections.

Kassamali Z, Danziger LH, Glowacki RC, Schwartz DN.

Int J Infect Dis. 2013 Aug;17(8):e615-20. doi: 10.1016/j.ijid.2013.01.015. Epub 2013 Mar 7.

31.

A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009.

Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Danziger LH.

J Antimicrob Chemother. 2013 Mar;68(3):715-8. doi: 10.1093/jac/dks445. Epub 2012 Nov 11.

PMID:
23148204
32.
33.

Tigecycline: a novel broad-spectrum antimicrobial.

Slover CM, Rodvold KA, Danziger LH.

Ann Pharmacother. 2007 Jun;41(6):965-72. Epub 2007 May 22. Review.

PMID:
17519296
34.

Micafungin: a new echinocandin antifungal.

Joseph JM, Jain R, Danziger LH.

Pharmacotherapy. 2007 Jan;27(1):53-67. Review.

PMID:
17192162
35.

Pharmacists' perceptions of the effectiveness of antimicrobial control programs.

Itokazu GS, Schwartz DN, Garey KW, Rodvold KA, Danziger LH, Weinstein RA.

Am J Health Syst Pharm. 2006 Dec 15;63(24):2504-8.

PMID:
17158699
36.

Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.

Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH, Rodvold KA.

Diagn Microbiol Infect Dis. 2006 Aug;55(4):303-9.

PMID:
16887471
37.

Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone.

Suda KJ, Garey KW, Danziger LH.

Pharm World Sci. 2005 Apr;27(2):81-2.

PMID:
15999916
38.

Daptomycin: a novel cyclic lipopeptide antimicrobial.

Schriever CA, Fernández C, Rodvold KA, Danziger LH.

Am J Health Syst Pharm. 2005 Jun 1;62(11):1145-58. Review.

PMID:
15914875
39.

Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases.

Cannon JP, Lee TA, Bolanos JT, Danziger LH.

Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):31-40. Review.

PMID:
15599646
40.

Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.

Lodise TP Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL.

Antimicrob Agents Chemother. 2004 Dec;48(12):4718-24.

41.

Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.

Sprandel KA, Schriever CA, Pendland SL, Quinn JP, Gotfried MH, Hackett S, Graham MB, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2004 Dec;48(12):4597-605.

42.

The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview.

Jain R, Danziger LH.

Curr Pharm Des. 2004;10(25):3045-53. Review.

PMID:
15544496
43.

Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.

Jain R, Danziger LH.

Ann Pharmacother. 2004 Sep;38(9):1449-59. Epub 2004 Jul 27. Review.

PMID:
15280512
44.

Markers of inflammation in exhaled breath condensate of young healthy smokers.

Garey KW, Neuhauser MM, Robbins RA, Danziger LH, Rubinstein I.

Chest. 2004 Jan;125(1):22-6.

PMID:
14718416
45.

Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study.

Gotfried MH, Jung R, Messick CR, Rubinstein I, Garey KW, Rodvold KA, Danziger LH.

Curr Ther Res Clin Exp. 2004 Jan;65(1):1-12. doi: 10.1016/S0011-393X(04)90000-8.

47.

Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects.

Gotfried MH, Danziger LH, Rodvold KA.

J Antimicrob Chemother. 2003 Sep;52(3):450-6. Epub 2003 Jul 29.

PMID:
12888589
48.

Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Rodvold KA, Danziger LH, Gotfried MH.

Antimicrob Agents Chemother. 2003 Aug;47(8):2450-7.

49.

Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.

Cannon JP, Fiscella R, Pattharachayakul S, Garey KW, De Alba F, Piscitelli S, Edward DP, Danziger LH.

Invest Ophthalmol Vis Sci. 2003 May;44(5):2112-7.

PMID:
12714650
50.

In vitro bactericidal activities of ABT-773 against ermB strains of Streptococcus pneumoniae.

Neuhauser MM, Prause JL, Danziger LH, Pendland SL.

Antimicrob Agents Chemother. 2003 Mar;47(3):1132-4.

Supplemental Content

Loading ...
Support Center